AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients Topline data from ROC-101 Phase 1 study demonstrate favorable safety and tolerability, and no associated hypotension Leadership team comprises executives…